Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Miyake

Showing results (31-40 of 587) with videos related to

Pageof 59
Sort By:
Urologic Oncology|February 8, 2017
Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitorsTakuto Hara, Hideaki Miyake, Masato Fujisawa
Current Urology|June 1, 2017
Geriatric Nutrition Risk Index is an Important Predictor of Cancer-Specific Survival, but not Recurrence-Free Survival, in Patients Undergoing Surgical Resection for Non-Metastatic Renal Cell CarcinomaHideaki Miyake, Hiromoto Tei, Masato Fujisawa
Targeted Oncology|October 2, 2015
Acceleration of Proteinuria without Significant Impact on Renal Function and Its Protection by Angiotensin II Receptor Blocker in Rats Treated with AxitinibSatoshi Imai, Hideaki Miyake, Masato Fujisawa
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 28, 2016
[Ligand-independent activation of androgen receptor]Tomoaki Terakawa, Hideaki Miyake, Masato Fujisawa
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 28, 2016
[Cabazitaxel]Kenichi Harada, Hideaki Miyake, Masato Fujisawa
International Journal of Urology : Official Journal of the Japanese Urological Association|February 6, 2024
Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancerTaigo Kato, Ryuichi Mizuno, Hideaki Miyake
Urologic Oncology|May 16, 2016
De Ritis (aspartate transaminase/alanine transaminase) ratio as a significant predictor of recurrence-free survival in patients with upper urinary tract urothelial carcinoma following nephroureterectomyMasatomo Nishikawa, Hideaki Miyake, Masato Fujisawa
International Journal of Urology : Official Journal of the Japanese Urological Association|March 27, 2003
Prediction of the extent of prostate cancer by the combined use of systematic biopsy and serum level of cathepsin DHideaki Miyake, Isao Hara, Hiroshi Eto
Anticancer Research|August 28, 2004
Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progressionHideaki Miyake, Isao Hara, Hiroshi Eto
BJU International|September 13, 2005
Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancerHideaki Miyake, Isao Hara, Hiroshi Eto
Pageof 59

Showing results (31-40 of 587) with videos related to

Sort By:
Pageof 59
Urologic Oncology|February 8, 2017
Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitorsTakuto Hara, Hideaki Miyake, Masato Fujisawa
Current Urology|June 1, 2017
Geriatric Nutrition Risk Index is an Important Predictor of Cancer-Specific Survival, but not Recurrence-Free Survival, in Patients Undergoing Surgical Resection for Non-Metastatic Renal Cell CarcinomaHideaki Miyake, Hiromoto Tei, Masato Fujisawa
Targeted Oncology|October 2, 2015
Acceleration of Proteinuria without Significant Impact on Renal Function and Its Protection by Angiotensin II Receptor Blocker in Rats Treated with AxitinibSatoshi Imai, Hideaki Miyake, Masato Fujisawa
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 28, 2016
[Ligand-independent activation of androgen receptor]Tomoaki Terakawa, Hideaki Miyake, Masato Fujisawa
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 28, 2016
[Cabazitaxel]Kenichi Harada, Hideaki Miyake, Masato Fujisawa
International Journal of Urology : Official Journal of the Japanese Urological Association|February 6, 2024
Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancerTaigo Kato, Ryuichi Mizuno, Hideaki Miyake
Urologic Oncology|May 16, 2016
De Ritis (aspartate transaminase/alanine transaminase) ratio as a significant predictor of recurrence-free survival in patients with upper urinary tract urothelial carcinoma following nephroureterectomyMasatomo Nishikawa, Hideaki Miyake, Masato Fujisawa
International Journal of Urology : Official Journal of the Japanese Urological Association|March 27, 2003
Prediction of the extent of prostate cancer by the combined use of systematic biopsy and serum level of cathepsin DHideaki Miyake, Isao Hara, Hiroshi Eto
Anticancer Research|August 28, 2004
Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progressionHideaki Miyake, Isao Hara, Hiroshi Eto
BJU International|September 13, 2005
Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancerHideaki Miyake, Isao Hara, Hiroshi Eto
Pageof 59